Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of bimekizumab in adult moderate to severe plaque psoriasis
2016-003427-30Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bimekizumab in psoriasis, sponsored by UCB. Primary endpoint: Treatment-emergent adverse events adjusted by exposure. Started Jul 2018; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2016-003427-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003427-30.